 Nicotinic Agonists
"Nicotinic Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
| Descriptor ID |
D018722
|
| MeSH Number(s) |
D27.505.519.625.120.140.700 D27.505.696.577.120.140.700
|
| Concept/Terms |
Nicotinic Agonists- Nicotinic Agonists
- Agonists, Nicotinic
- Cholinergic Agonists, Nicotinic
- Agonists, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonists
- Nicotinic Agonist
- Agonist, Nicotinic
- Cholinergic Agonist, Nicotinic
- Agonist, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonist
|
Below are MeSH descriptors whose meaning is more general than "Nicotinic Agonists".
Below are MeSH descriptors whose meaning is more specific than "Nicotinic Agonists".
This graph shows the total number of publications written about "Nicotinic Agonists" by people in this website by year, and whether "Nicotinic Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 3 | 2 | 5 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 2 | 4 | | 2005 | 1 | 0 | 1 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 3 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 5 | 0 | 5 | | 2010 | 2 | 0 | 2 | | 2011 | 3 | 0 | 3 | | 2012 | 6 | 1 | 7 | | 2013 | 3 | 1 | 4 | | 2014 | 5 | 0 | 5 | | 2015 | 4 | 2 | 6 | | 2016 | 1 | 1 | 2 | | 2017 | 6 | 3 | 9 | | 2019 | 2 | 0 | 2 | | 2020 | 3 | 1 | 4 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Nicotinic Agonists" by people in Profiles.
-
Rusy DA, Honkanen A, Landrigan-Ossar MF, Chatterjee D, Schwartz LI, Lalwani K, Dollar JR, Clark R, Diaz CD, Deutsch N, Warner DO, Soriano SG. Vaping and E-Cigarette Use in Children and Adolescents: Implications on Perioperative Care From the American Society of Anesthesiologists Committee on Pediatric Anesthesia, Society for Pediatric Anesthesia, and American Academy of Pediatrics Section on Anesthesiology and Pain Medicine. Anesth Analg. 2021 09 01; 133(3):562-568.
-
Tackenberg MC, Giannoni-Guzmán MA, Sanchez-Perez E, Doll CA, Agosto-Rivera JL, Broadie K, Moore D, McMahon DG. Neonicotinoids disrupt circadian rhythms and sleep in honey bees. Sci Rep. 2020 10 21; 10(1):17929.
-
Morris CD, Garver-Apgar CE. Nicotine and Opioids: a Call for Co-treatment as the Standard of Care. J Behav Health Serv Res. 2020 10; 47(4):601-613.
-
Rahman MM, Teng J, Worrell BT, Noviello CM, Lee M, Karlin A, Stowell MHB, Hibbs RE. Structure of the Native Muscle-type Nicotinic Receptor and Inhibition by Snake Venom Toxins. Neuron. 2020 06 17; 106(6):952-962.e5.
-
Buck JM, O'Neill HC, Stitzel JA. Developmental nicotine exposure engenders intergenerational downregulation and aberrant posttranslational modification of cardinal epigenetic factors in the frontal cortices, striata, and hippocampi of adolescent mice. Epigenetics Chromatin. 2020 03 05; 13(1):13.
-
Moro F, Giannotti G, Caffino L, Marzo CM, Di Clemente A, Fumagalli F, Cervo L. Lasting reduction of nicotine-seeking behavior by chronic N-acetylcysteine during experimental cue-exposure therapy. Addict Biol. 2020 07; 25(4):e12771.
-
Tregellas JR, Wylie KP. Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia. Nicotine Tob Res. 2019 02 18; 21(3):349-356.
-
Lewis AS, Olincy A, Buchanan RW, Kem WR, Picciotto MR, Freedman R. Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia. Schizophr Res. 2018 05; 195:568-569.
-
Kress CM, Obi NU, Prochazka AV. In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT. Ann Intern Med. 2017 09 19; 167(6):JC31.
-
Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, Hutchison KE. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. Psychopharmacology (Berl). 2017 Dec; 234(23-24):3417-3429.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|